US 12,403,150 B2
Tryptamine compositions for enhancing neurite outgrowth
Paul Edward Stamets, Shelton, WA (US)
Assigned to TURTLE BEAR HOLDINGS, LLC, Shelton, WA (US)
Filed by TURTLE BEAR HOLDINGS, LLC, Shelton, WA (US)
Filed on Jan. 29, 2025, as Appl. No. 19/040,329.
Application 19/040,329 is a continuation of application No. 18/475,724, filed on Sep. 27, 2023, granted, now 12,257,258.
Application 18/475,724 is a continuation of application No. 17/570,054, filed on Jan. 6, 2022, granted, now 11,911,401, issued on Feb. 27, 2024.
Application 17/570,054 is a continuation of application No. 16/951,009, filed on Nov. 18, 2020, granted, now 11,660,305, issued on May 30, 2023.
Claims priority of provisional application 63/007,482, filed on Apr. 9, 2020.
Claims priority of provisional application 62/937,536, filed on Nov. 19, 2019.
Prior Publication US 2025/0205254 A1, Jun. 26, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/661 (2006.01); A61K 9/08 (2006.01); A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61K 31/4045 (2006.01); A61K 31/455 (2006.01); A61K 36/06 (2006.01); A61K 36/066 (2006.01); A61K 36/07 (2006.01); A61K 36/185 (2006.01); A61K 36/73 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/661 (2013.01) [A61K 9/08 (2013.01); A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61K 31/4045 (2013.01); A61K 31/455 (2013.01); A61K 36/06 (2013.01); A61K 36/066 (2013.01); A61K 36/07 (2013.01); A61K 36/185 (2013.01); A61K 36/73 (2013.01); A61P 25/24 (2018.01)] 18 Claims
 
1. A method for treating or ameliorating one or more symptoms of a serotonin (5-hydroxytryptamine, 5-HT) receptor disorder in a subject in need thereof, the method comprising: administering to the subject a pharmaceutical dosage form comprising:
0.01 mg to 10 mg of psilocin, psilocybin, salts thereof, or combinations thereof; and
one or more pharmaceutically acceptable excipients selected from carriers, fillers, binders, disintegrants, preservatives, or antioxidants;
wherein the serotonin (5-hydroxytryptamine, 5-HT) receptor disorder comprises depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression, bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depressions, situational depression, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, attention deficit/hyperactivity disorder, substance abuse disorders or combinations thereof.